Serum level of soluble interleukin 6 receptor is a useful biomarker for identification of treatment‐resistant major depressive disorder
Sign Up to like & getrecommendations! Published in 2020 at "Neuropsychopharmacology Reports"
DOI: 10.1002/npr2.12100
Abstract: A substantial proportion of major depressive disorder patients are treatment‐resistant to antidepressant therapy, who require augmentation drugs, or other treatments including electroconvulsive therapy or transcranial magnetic stimulation. Identifying treatment‐resistant major depressive disorder patients before the… read more here.
Keywords: resistant major; treatment resistant; depressive disorder; treatment ... See more keywords
Pets enhance antidepressant pharmacotherapy effects in patients with treatment resistant major depressive disorder.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of psychiatric research"
DOI: 10.1016/j.jpsychires.2018.07.004
Abstract: Treatment resistant major depressive disorder (TR-MDD) is a severe disease, with very low remission rates. The resistance to pharmacotherapy leads to the search of non-pharmacological alternative approaches. Animal therapy has been used in patients with… read more here.
Keywords: resistant major; treatment resistant; depressive disorder; major depressive ... See more keywords
A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression
Sign Up to like & getrecommendations! Published in 2021 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abe1376
Abstract: Twenty-five percent inhaled nitrous oxide improves symptoms of treatment-resistant major depression with fewer adverse effects than the 50% concentration. Laughing gas improves depression About one-third of individuals suffering from depression are at risk for treatment… read more here.
Keywords: resistant major; treatment resistant; nitrous oxide; treatment ... See more keywords
Mitigating the Risk of Adverse Effects Related to Augmentation Therapy for Resistant Major Depressive Disorder: A Case Report
Sign Up to like & getrecommendations! Published in 2022 at "Medicina"
DOI: 10.3390/medicina58030438
Abstract: Polypharmacy of psychotropic medications predisposes older adults to adverse drug events (ADEs). One contributing factor is inhibition of metabolic pathways between substrates (competitive inhibition) or between substrates and inhibitors of the same cytochrome P450 (CYP450)… read more here.
Keywords: case report; augmentation therapy; resistant major; therapy ... See more keywords